UNITED STATES ~~SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549~~

~~————~~SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

~~PURSUANT~~Pursuant TOto ~~SECTION~~ Section 13 ORor 15(d) ~~OF THE~~ of

~~SECURITIES~~The ~~EXCHANGE~~Securities ~~ACT~~Exchange OFAct of 1934

Date of Report (Date of ~~Earliest~~earliest ~~Event~~event ~~Reported~~reported): ~~March 4~~ April 27, 2011

TALECRIS BIOTHERAPEUTICS HOLDINGS CORP.

(Exact ~~Name~~name of ~~Registrant~~registrant as ~~Specified~~specified in its ~~Charter~~charter)

Delaware		001-34473		20-2533768
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification Number)

Delaware
(State or other
jurisdiction of incorporation)

001-34473
(Commission
File Number)

20-2533768
(I.R.S. Employer
Identification No.)

4101 Research Commons 79 T.W. Alexander Drive

P.O. Box 110526 4101 Research Commons 79 T.W. Alexander Drive Research Triangle Park, North Carolina		27709
(Address of principal executive offices)		(Zip Code)

~~Research~~Registrant’s ~~Triangle~~telephone ~~Park~~number, ~~North~~including ~~Carolina 27709~~area code: (919) 316-6300

~~(Address~~Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of ~~principal~~the ~~executive~~registrant ~~offices~~under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (~~919)~~17 ~~316-6300~~ CFR 230.425)

~~(Registrant's~~o Soliciting ~~telephone~~material ~~number,~~pursuant ~~including~~to ~~area~~Rule 14a-12 ~~code)~~under the Exchange Act (17 CFR 240.14a-12)

~~Check the appropriate box below if the Form 8~~o Pre-Kcommencement ~~filing~~communications ispursuant ~~intended~~ to ~~simultaneously~~Rule 14d-2(b) under ~~satisfy~~ the ~~filing~~Exchange ~~obligation~~Act of(17 ~~the~~CFR ~~registrant under any of the following provisions:~~240.14d-2(b))

~~¨ Written~~o Pre-commencement communications pursuant to Rule ~~425~~ 13e-4(c) under the ~~Securities~~Exchange Act (17 CFR ~~230~~240.~~425~~13e-4(c))

~~¨ Soliciting~~Item ~~material~~2.02 ~~pursuant~~Results toof ~~Rule~~Operations ~~14a-12~~and ~~under~~Financial ~~the Exchange Act (17 CFR 240~~Condition.~~14a-12)~~

~~¨ Pre-commencement~~On ~~communications~~April 27, ~~pursuant~~2011, toTalecris ~~Rule~~Biotherapeutics ~~14d-2(b)~~Holdings ~~under~~Corp. issued a press release announcing its financial results for the ~~Exchange~~three ~~Act~~months ~~(17~~ended ~~CFR~~March 31, ~~240~~2011.~~14d~~ A copy of the press release is furnished as Exhibit 99.1 to this Form 8-~~2(b))~~K.

~~¨ Pre-commencement~~The ~~communications~~information ~~pursuant~~in tothis ~~Rule~~report, ~~13e-4(c)~~including ~~under~~Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act ~~(17~~of ~~CFR~~1934, ~~240~~as amended, nor shall it be incorporated by reference in any registration statement filed under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated by reference therein.~~13e-4(c))~~

~~ITEM~~Item 89.01. ~~other~~Financial ~~events~~Statements and Exhibits.

~~On March 4, 2011, Talecris Biotherapeutics Holdings Corp.~~ (~~“Talecris”~~d) and Grifols, S.A. (“Grifols”) jointly announced that the “outside date” of their pending merger transaction has been extended to June 30, 2011 (from March 6, 2011) and that Grifols had extended the financing and financing commitments from its lenders to June 30, as well. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference Exhibits

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

No.		Description

99.1		Press Release dated April 27, 2011

~~(d)~~Pursuant ~~Exhibits~~to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Exhibits to this Form 8-K
		TALECRIS BIOTHERAPEUTICS HOLDINGS CORP.
Exhibit No.	Description
		By:	/s/ John M. Hanson
99.1	Press Release, dated March 4, 2011
		Name:			John M. Hanson
		Title:		Executive Vice President and Chief Financial Officer
Date:	April 27, 2011

~~SIGNATURE~~ EXHIBIT INDEX

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

No.		Description

99.1		Press Release dated April 27, 2011

~~Talecris Biotherapeutics Holdings Corp. (Registrant) Date: March 4, 2011 /s/ John F. Gaither, Jr. Name: John F. Gaither, Jr. Title: Executive Vice President, General Counsel and Corporate Secretary~~3

EXHIBIT INDEX

Exhibits to this Form 8-K
Exhibit No.	Description
99.1	Press Release, dated March 4, 2011

Filing Compare · Talecris Biotherapeutics Holdings Corp.